Doximity's Soft Fiscal Q4 Guidance Adds to Investor Concerns, Morgan Stanley Says

MT Newswires Live02-07

Doximity's (DOCS) weak fiscal Q4 guidance "will further fuel the bear-case concerns" that the company is losing market share, Morgan Stanley said Friday in a report.

"Combined with a messy guide accompanied by the CFO's medical leave of absence, the stock is likely to overreact," Morgan Stanley said.

Still, an "overreaction provides an opportunity," the report said.

Management said January showed the strongest pharma bookings growth ever, and Doximity is planning to roll out a commercial AI product in 2026, Morgan Stanley said.

Investors received better disclosure on DoxGPT, and the monetization prospects are an "upside driver," and "meaningful pullback" on the shares represent a buying opportunity, the report said.

Doximity shares slumped 23% in Friday trading.

Morgan Stanley cut its price target on Doximity stock to $49 from $65 and maintained its overweight rating.

Price: 25.75, Change: -7.57, Percent Change: -22.72

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment